United States patent law

Fullpower®-AI Announces Issuance of Five New Patents, Enhancing Its Leadership in Sleep and Wellness Technologies

Retrieved on: 
Thursday, May 2, 2024
Meditation, Health, United States patent law, Environment, Science, Patent, Temperature, Sleep, Pet, Data collection, Pharmaceutical industry

These patents underscore Fullpower®-AI's commitment to advancing the science of sleep and wellness through cutting-edge technology.

Key Points: 
  • These patents underscore Fullpower®-AI's commitment to advancing the science of sleep and wellness through cutting-edge technology.
  • US Patent 11,972,775 - This patent introduces an innovative system for collecting sleep data in noisy environments.
  • Issued on April 23, 2024, this patent emphasizes Fullpower®-AI's dedication to improving sleep quality regardless of environmental disturbances.
  • "These patents represent significant technological advancements and reinforce our leadership in the sleep and wellness industries," said Philippe Kahn, CEO of Fullpower®-AI.

Vizgen Issued a New US Patent for Its MERFISH Technology

Retrieved on: 
Tuesday, April 16, 2024
Research, Patent Law, Genetics, Health Technology, Professional Services, Biotechnology, Health, Other Science, Science, United States patent law, RNA, Harvard College, Patent, Chemistry, PTAB, AACR, Harvard University, Inter partes review

Vizgen has secured key patents protecting its innovative pioneering technology in the United States and abroad, adding to its growing patent portfolio as Vizgen continues to invest in the development of its groundbreaking technologies.

Key Points: 
  • Vizgen has secured key patents protecting its innovative pioneering technology in the United States and abroad, adding to its growing patent portfolio as Vizgen continues to invest in the development of its groundbreaking technologies.
  • This newly allowed patent is owned by The President and Fellows of Harvard College and is exclusively licensed to Vizgen.
  • To date, there are over two hundred peer-reviewed and preprint publications on MERFISH technology and thousands of samples have been processed on MERSCOPE instruments.
  • During AACR 2024, Vizgen unveiled the MERSCOPE® Ultra Platform and shared new MERFISH 2.0 chemistry data.

Exactech Strengthens Position as Soft Tissue Balancing Technology Leader with New Patents

Retrieved on: 
Monday, April 22, 2024
Patent, Orientation, Patient satisfaction, Patient, Motion, United States patent law, 3D printing

The two newly granted patents build on a previously awarded patent by broadening the scope of position and orientation of the mechanical actuators in the company's Newton soft tissue balancing device.

Key Points: 
  • The two newly granted patents build on a previously awarded patent by broadening the scope of position and orientation of the mechanical actuators in the company's Newton soft tissue balancing device.
  • "Exactech is committed to leading the industry with innovative soft tissue management technologies that address the growing need for improved patient satisfaction and outcomes in knee replacement," said Laurent Angibaud, Vice President of Advanced Surgical Technologies Development at Exactech.
  • "These newly awarded patents add to Exactech's strong IP portfolio of more than 45 global patents that are dedicated to soft-tissue management, protecting our innovations that offer patients the balanced outcomes they deserve."
  • Powered by Active Intelligence® , the Newton Knee technique works in concert with ExactechGPS® to provide orthopaedic surgeons with dynamic soft tissue analytics, pre-resection operative insights and full-range personalized planning designed to simplify, evaluate and execute balanced total knee replacement surgery.

Privacy4Cars Awarded Three More Patents as New Regulations Require Deletion of Consumer Personal Data Stored in Vehicles in New Jersey and Illinois

Retrieved on: 
Thursday, April 18, 2024
Computer vision, IP, Mouth, News, AI, United States patent law, OEM, Software as a service, Artificial intelligence, Patent, Record, Privacy, IDS, Facial recognition, Trust, ALPR, System

ATLANTA, April 18, 2024 /PRNewswire-PRWeb/ -- Privacy4Cars, the first privacy-tech company focused on solving the privacy and security issues posed by vehicle data to protect consumers and automotive businesses, announced today the US Patent Office approved three new patents.

Key Points: 
  • It includes the world's first privacy labeling system covering circa 600 million vehicles across the US, Canada, the UK, and the EU.
  • The third patent is an expansion of the company's signature method to delete personal information stored in vehicles and to create records of deletion.
  • Hundreds of companies already rely on Privacy4Cars' AutoCleared™ data deletion service - and its distinctive IP now includes six patents.
  • Privacy4Cars' newly-awarded patents will fuel the expansion of its product offering, adding to its already robust suite of privacy tools.

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

Retrieved on: 
Thursday, April 18, 2024
CRC, STS, Food, United States patent law, Orphan, Research, AML, Anthracycline, European, EMA, Virus, Patent, Diagnosis, Orphan drug, European Medicines Agency, Pharmaceutical industry

HOUSTON, April 18, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of AML.

Key Points: 
  • Recruitment in MB-106 has ended for 2nd line subjects while recruitment for 1st line and 3rd line subjects continue.
  • The EMA grants orphan drug designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare, life-threatening or chronically debilitating diseases or conditions that affect fewer than five in 10,000 people in the European Union.
  • Orphan designation allows companies certain benefits, including reduced regulatory fees, clinical protocol assistance, research grants and up to 10 years of potential market exclusivity in the European Union if approved.
  • Annamycin currently has Fast Track Status and Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of relapsed or refractory AML, in addition to Orphan Drug Designation for the treatment of STS lung mets.

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

Retrieved on: 
Wednesday, April 10, 2024
Cardiotoxicity, RTCA, Mouse, STS, Doxorubicin, Heart, Animal, Molecule, Pathology, AML, Potent, Anthracycline, DNA, Patent, Patient, Physiology, Virus, Toxicity, Acute myeloid leukemia, AACR, United States patent law, Pharmaceutical industry

HOUSTON, April 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced positive preclinical data regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego, CA.

Key Points: 
  • The poster titled, Non-cardiotoxic Properties of Annamycin, a Clinically Evaluated Anthracycline and Potent Topoisomerase 2β Poison , was presented in the "Late-Breaking Research: Experimental and Molecular Therapeutics 2" session held on Monday, April 8th.
  • These data, documenting lack of cardiotoxicity of Annamycin and aligned with the data demonstrated to date in our ongoing clinical trials, bolster our confidence in Annamycin potential to offer patients a safe and effective treatment option.
  • Annamycin and doxorubicin cytotoxicity was assessed in a panel of cancer cell lines cardiomyocytes (murine and human).
  • For more information about the ongoing trials, please visit clinicaltrialsregister.eu : EudraCT 2020-005493-10 or clinicaltrials.gov : NCT05319587; and clinicaltrials.gov : NCT04887298, respectively.

EQS-News: Australian Patent Update

Retrieved on: 
Wednesday, April 10, 2024
Government, Exercise, Federal court, Commissioner, Patent, ASX, United States patent law, Disclosure, EGR, FMK

EcoGraf Limited (“EcoGraf” or the “Company”) (ASX: EGR; FSE: FMK; OTCQB: ECGFF) advises that the delegate of the Australian Commissioner of Patents has issued findings in favour of opposition raised to the Company’s Australian patent application, filed on 1 November 2022 and entitled “Method of Producing Purified Graphite”.

Key Points: 
  • EcoGraf Limited (“EcoGraf” or the “Company”) (ASX: EGR; FSE: FMK; OTCQB: ECGFF) advises that the delegate of the Australian Commissioner of Patents has issued findings in favour of opposition raised to the Company’s Australian patent application, filed on 1 November 2022 and entitled “Method of Producing Purified Graphite”.
  • For full details refer:
    EcoGraf is considering its position in relation to the matter, specifically whether or not it intends to file amendments to overcome the deficiencies identified by the delegate in the Company’s Australian patent application and/or whether to exercise its right of appeal to the Federal Court.
  • The US Patent and Trademark Office has confirmed that the Company’s patent application, filed on 1 November 2022, entitled “Method of Producing Purified Graphite” was granted on 18 July 2023 as US Patent 11,702342 (refer ASX announcement US Patent Granted 19 July 2023).
  • The Company’s EcoGraf HFfree™ Australian Product Qualification Facility is being developed with the support of a $2.9m grant provided by the Australian Government under the Critical Minerals Development Program, with commissioning scheduled to commence next month.

Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration

Retrieved on: 
Tuesday, April 9, 2024
MD, MIT, Patent, Composition, PASTE, PGI, DNA, State, United States patent law

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.

Key Points: 
  • WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.
  • This patent further protects Tome’s foundational PGI technology, integrase-mediated PGI (I-PGI), describes a system capable of performing I-PGI in a mammalian cell, and is exclusively licensed to Tome from MIT.
  • “Today’s issuance marks the fourth US patent granted that encompasses our I-PGI technology, strengthening our patent portfolio and broadening our exclusivity,” said Rahul Kakkar, MD, President and Chief Executive Officer of Tome.
  • Together, with US Patent 11,952,571, these patents cover methods and systems relating to the use of a Cas 9 nickase, reverse transcriptase and an integrase to integrate DNA sequences into programmed locations.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, April 2, 2024
Vagus nerve, Central nervous system, Fibromyalgia, Patent, TBI, Anxiety, Software, United States patent law, ElectroCore, PTSD, Medical device

ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

Key Points: 
  • ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
  • The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology:
    US Patent No.
  • The therapy regimen comprises generating an electrical signal for approximately 5 minutes to 30 minutes.
  • The electrical impulses are bursts of 2 to 20 sinusoidal pulses.

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Commitment, Research, Obesity, PTE, Exercise, Bariatrics, Patent, Patient, Food and Drug Administration, Weight loss, Travel, Acquisition, FLEX, Prescription, NYU, Food, Security (finance), Insurance, Marketing, Surgeon, C-peptide, Annual report, PMA, NYU Langone Health, Division, United States patent law, FDA, Advertising, Bariatric surgery

IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate strategic update.

Key Points: 
  • Specifically, it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819.
  • December 2023: Engaged Maxim Group LLC, to act as the company’s exclusive financial advisor to help identify potential synergistic merger and acquisition partnerships.
  • December 2023: Received U.S. Food and Drug Administration (FDA) PMA supplement approval for its next-generation Lap-Band® 2.0 FLEX, designed to improve the patient experience.
  • Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.